These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 34429653)

  • 1. Analysis of m6A-Related lncRNAs for Prognosis Value and Response to Immune Checkpoint Inhibitors Therapy in Hepatocellular Carcinoma.
    Wang Y; Li N; Tian D; Zhou CW; Wang YH; Yang C; Zeng MS
    Cancer Manag Res; 2021; 13():6451-6471. PubMed ID: 34429653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
    BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
    Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
    Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of m
    Wu X; Wang S; Wu X; Chen Q; Cheng J; Qi Z
    J Cancer; 2024; 15(7):2045-2065. PubMed ID: 38434979
    [No Abstract]   [Full Text] [Related]  

  • 7. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
    Liu Y; Wang T; Fang Z; Kong J; Liu J
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
    Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
    BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of 6 m6A-relevant lncRNA genes as prognostic markers of primary liver hepatocellular carcinoma based on TCGA database.
    Zhu XL; Li Q; Shen J; Shan L; Zuo ED; Cheng X
    Transl Cancer Res; 2021 Dec; 10(12):5337-5351. PubMed ID: 35116381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Validation of a Prognostic Prediction Model of m6A Regulator-Related LncRNAs in Hepatocellular Carcinoma.
    Jin C; Li R; Deng T; Li J; Yang Y; Li H; Chen K; Xiong H; Chen G; Wang Y
    Front Mol Biosci; 2021; 8():784553. PubMed ID: 34988119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer.
    Chen K; Zhu S; Yu W; Xia Y; Xing J; Geng J; Cheng F
    Front Oncol; 2022; 12():774307. PubMed ID: 35141159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs.
    Zhang L; Tang X; Wan J; Zhang X; Zheng T; Lin Z; Liu T
    Front Mol Biosci; 2021; 8():715764. PubMed ID: 34733885
    [No Abstract]   [Full Text] [Related]  

  • 14. N6-Methyladenosine-Related Long Non-coding RNA Signature Associated With Prognosis and Immunotherapeutic Efficacy of Clear-Cell Renal Cell Carcinoma.
    Ma T; Wang X; Wang J; Liu X; Lai S; Zhang W; Meng L; Tian Z; Zhang Y
    Front Genet; 2021; 12():726369. PubMed ID: 34721523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Analysis of N6-Methyladenosine-Related IncRNAs Prognostic Signature and the Associated Immune Infiltrates in Kidney Renal Clear Cell Carcinoma.
    Chen X; Wang L; Tu J; Pan X; Li Y; Yin H; Wang M; Yuan X
    Crit Rev Eukaryot Gene Expr; 2022; 32(1):79-98. PubMed ID: 35377983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.
    Yu ZL; Zhu ZM
    Bioengineered; 2021 Dec; 12(1):1708-1724. PubMed ID: 33955330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of RBM15 as a prognostic biomarker in prostate cancer involving the regulation of prognostic m6A-related lncRNAs.
    Hu B; Lin D; Liu Z; Chen R; Liu J; Wu Y; Wang T
    Eur J Med Res; 2024 Aug; 29(1):411. PubMed ID: 39118157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity.
    Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L
    Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696
    [No Abstract]   [Full Text] [Related]  

  • 19. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
    Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
    Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
    Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.